Zelluna ASA Implements New Share Capital Increase
Zelluna ASA, a burgeoning biotechnology firm, has made waves with its recent share capital increase. This vital development comes on the heels of a successful private placement that raised significant capital to further its innovative projects in cancer treatment.
Details of the Capital Increase
The company successfully raised funds through the issuance of 5,500,000 new shares, which were allocated into two distinct tranches. The first tranche consisted of 3,729,774 new shares, while the second tranche included 1,770,226 new shares. Additionally, 315,639 new shares were allocated through a retail offering executed via the PrimaryBid platform. This carefully structured offering underscored Zelluna ASA's intent to attract a wide range of investors to support its groundbreaking initiatives.
The Shares Now Registered
The total of 4,045,413 new shares resulting from this capital raising effort has now gained official registration with the Norwegian Register of Business Enterprises. With this wave of new shares, Zelluna ASA's total share capital is now NOK 24,499,575, distributed across 24,499,575 shares, each valued at NOK 1. This robust capital increase signifies a powerful boost for the company as it continues its mission to innovate in the biotechnology sector.
Elucidating Zelluna ASA’s Core Business
Zelluna ASA is not just raising capital; it is poised to reshape the realms of cancer treatment through its cutting-edge research and development. The company specializes in creating allogeneic T Cell Receptor-based Natural Killer (TCR-NK) cell therapies, which are groundbreaking innovations designed to combat the challenges presented by current cancer treatment methodologies.
Innovative Cancer Treatments
With its unique approach, Zelluna ASA combines the innate destructive capabilities of Natural Killer cells with the precise targeting of T Cell Receptors. This method particularly addresses the inefficiencies associated with existing cell therapies, especially in targeting solid tumors. Such advancements are crucial in ensuring that more patients have access to effective treatments.
Looking Ahead: Clinical Trials and Future Prospects
One of the most exciting developments stemming from Zelluna ASA’s research is the anticipated entry into clinical trials of their lead program, ZI-MA4-1, which specifically targets the MAGE-A4 tumor antigen. These trials are expected to commence in the near future, heralding an important step forward in bringing this innovative therapy to market.
Pioneering Production Techniques
Another noteworthy aspect of Zelluna ASA’s operations is its proprietary manufacturing process. This technology enables efficient and scalable production of TCR-NK cell therapies, promoting cost-effectiveness and broad accessibility for patients. By improving the affordability of such advanced therapies, Zelluna ASA stands to make a significant impact in the biotechnology and healthcare fields.
Contact Information for Investors and Stakeholders
For those interested in learning more about Zelluna ASA or connecting with the company's leadership, the following contact details are provided:
Namir Hassan, CEO, Zelluna ASA
Email: namir.hassan@zelluna.com
Phone: +44 7720 687608
Hans Vassgård Eid, CFO, Zelluna ASA
Email: hans.eid@zelluna.com
Phone: +47 482 48632
Frequently Asked Questions
What does Zelluna ASA focus on in biotechnology?
Zelluna ASA is dedicated to developing innovative TCR-NK cell therapies aimed at treating cancer.
What was the total number of new shares issued in the recent placement?
The company issued a total of 5,500,000 new shares during the private placement and retail offering.
When is Zelluna ASA expected to start clinical trials for its lead program?
Clinical trials for the lead program, ZI-MA4-1, are anticipated to begin soon.
How much is Zelluna ASA's new share capital?
The new share capital is NOK 24,499,575, divided into 24,499,575 shares.
Who can be contacted for more information on Zelluna ASA?
Namir Hassan (CEO) and Hans Vassgård Eid (CFO) are the primary contacts for inquiries.
